Lumicell Inc.’s breast cancer imaging drug met its mark in its pivotal study, the US Food and Drug Administration said ahead of an advisory committee review, but the agency is not clear whether that mark represents a meaningful benefit to patients.
The mixed efficacy review, combined with safety concerns, could make for a challenging advisory panel for the sponsor on 5...